Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Comparing Medications for Adults With Type 2 Diabetes

Slide: 27 of 35

Gastrointestinal Adverse Events: Comparisons of Monotherapies

Gastrointestinal (GI) Side Effects
High-grade evidence showed that metformin was associated with more frequent GI adverse events compared with thiazolidinediones. High strength of evidence demonstrated that the rates of GI adverse effects were similar between thiazolidinediones and sulfonylureas. Moderate strength of evidence showed that metformin was associated with more frequent GI adverse events compared with second-generation sulfonylureas. Moderate strength of evidence showed that metformin was associated with more frequent GI adverse events compared with DPP-4 inhibitors.